tolterodine palmoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tolterodine palmoate
• 英文别名: 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
• 化学式: C₂₂H₃₁NO*C₂₃H₁₆O₆
• 分子量: 876.618
• InChiKey: JYACOSLTEJDZTB-BJFWBBLWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.73
• 重原子数：
  53
• 可旋转键数：
  11
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  139
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  托特罗定 、 帕莫酸 以 水 为溶剂， 反应 4.0h， 以87.27%的产率得到tolterodine palmoate
  参考文献：
  名称：

  一种托特罗定帕莫酸盐及其制备方法

  摘要：

  本发明涉及一种托特罗定帕莫酸盐和以托特罗定为原料制备托特罗定帕莫酸盐的制备方法，所得的托特罗定帕莫酸盐纯度高，溶解度降低，收率高。

  公开号：

  CN111925294A

文献信息

• Tolterodine salts
  申请人：——

  公开号：US20030199582A1

  公开（公告）日：2003-10-23

  The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are pharmaceutically acceptable salts of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting of aliphatic mono- and dicarboxylic acids comprising from 7 to 24 carbon atoms, alkanedisulfonic acids comprising from 2 to 4 carbon atoms, naphthoic acid derivatives comprising from 11 to 27 carbon atoms, maleic acid and fumaric acid.

  本发明涉及新型药用活性化合物、含有这些化合物的药物组合物、用作药物的化合物以及使用这些化合物制造特定药物。本发明还涉及一种涉及施用这些化合物的治疗方法。 具体地说，本发明化合物是托特罗定或羟基托特罗定的药学上可接受的盐，其中盐是选自以下组别的酸：由 7 至 24 个碳原子组成的脂肪族单羧酸和二羧酸、由 2 至 4 个碳原子组成的烷二磺酸、由 11 至 27 个碳原子组成的萘酸衍生物、马来酸和富马酸。
• TOLTERODINE SALTS
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1496882A1

  公开（公告）日：2005-01-19
• US7005449B2
  申请人：——

  公开号：US7005449B2

  公开（公告）日：2006-02-28
• [EN] TOLTERODINE SALTS<br/>[FR] SELS DE TOLTERODINE
  申请人：UPJOHN CO

  公开号：WO2003090734A1

  公开（公告）日：2003-11-06

  The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are pharmaceutically acceptable salts of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting of aliphatic mono- and dicarboxylic acids comprising from 7 to 24 carbon atoms, alkanedisulfonic acids comprising from 2 to 4 carbon atoms, naphthoic acid derivatives comprising from 11 to 27 carbon atoms, maleic acid and fumaric acid.